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Abstract
Background: Controlling enzyme activity by ligand binding to a regulatory domain of choice may
have many applications e.g. as biosensors and as tools in regulating cellular functions. However,
until now only a small number of ligand-binding domains have been successfully linked to enzyme
activity. G protein-coupled receptors (GPCR) are capable of recognizing an extraordinary
structural variety of extracellular signals including inorganic and organic molecules. Ligand binding
to GPCR results in conformational changes involving the transmembrane helices. Here, we
assessed whether ligand-induced conformational changes within the GPCR helix bundle can be
utilized to control the activity of an integrated enzyme.
Results: As a proof of principle, we inserted the luciferase amino acid sequence into the third
intracellular loop of the M3 muscarinic acetylcholine receptor. This fusion protein retained both
receptor and enzyme function. Receptor blockers slightly but significantly reduced enzyme activity.
By successive deletion mutagenesis the enzyme activity was optimally coupled to ligand-induced
conformational helix movements.
Conclusion: Our results demonstrate that in engineered GPCR-enzyme chimeras, intracellular
enzyme activity can be directly controlled by a GPCR serving as the extracellular ligand-binding
domain.
Background
Synthetic protein biosensors are typically designed by fus-
ing a target-binding domain to an easily assayed reporter
protein. The ligand-binding domain is often derived from
a specific receptor protein. Most biosensors are comple-
mentation systems where enzyme or fluorophore activity
is reconstituted from non-functional domains secondary
to receptor dimerization or conformational changes upon
ligand binding [1,2]. However, the repertoires of both,
well characterized ligand-binding and reporter domains
that are suitable for the design of complementation sys-
tems are rather small. A modular system that allows arbi-
trary combination of ligand-binding and reporter
domains would thus be most desirable. There are a few
examples of properly constructed receptor-enzyme chime-
ras which allow for the transduction of ligand-induced
conformational changes within the receptor to the
reporter protein and allosteric modulation of its proper-
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changes to reporter protein function appears to be the
general bottleneck in designing such biosensors.
Among the different families of transmembrane receptors,
G protein-coupled receptors (GPCR) form the largest
receptor superfamily comprising over 1000 members
within several vertebrate genomes [6-8]. Signals as multi-
form as light, small molecules including ions, amines,
amino acids, peptides, lipids, sugars, as well as large pro-
teins are recognized by receptors of this class [9,10]. Upon
agonist binding to the extracellular portion of GPCR, con-
formational changes of the transmembrane helix (TMH)
bundle and intracellular loop (ICL) portions lead to G-
protein activation [11-16]. Conformational changes of
the TMH bundle are not only observed after agonist bind-
ing but also after binding of inverse agonists that do not
result in G-protein activation [17-19]. In addition, GPCR
can be modified by site-directed mutagenesis to respond
to biologically inert compounds instead of their native
agonists [20,21]. The combination of these properties
favours GPCR as ideal ligand-binding modules in hybrid
biosensors.
In a number of studies, enzymes, such as luciferases,
galactosidase, alkaline phosphatase and peroxidase, as
well as fluorescent proteins (e.g. YFP) have been inte-
grated into GPCR. In these GPCR fusion proteins, the
enzyme or fluorescence activities were used as reporter
assay to monitor intracellular receptor trafficking [22,23]
and, in fluorescence and bioluminescence resonance
energy transfer (FRET/BRET) approaches, to monitor
GPCR-protein interactions [24-27]. Recently, the activity
of ion channels coupled to GPCR was modulated upon
ligand binding, demonstrating that GPCR are suitable
binding domains for biosensors [28].
Here, we report the allosteric modulation of enzyme activ-
ity upon ligand binding to a GPCR-enzyme chimera.
Using the M3 muscarinic acetylcholine receptor (M3R)
and luciferase as model proteins, we provide a proof of
concept that through rigid-body movement of the TMH
bundle, extracellular signals may be transduced onto an
enzyme that is integrated into the cytosolic portion of a
GPCR, thus changing enzyme activity.
Results and discussion
Functional integration of luciferase into the M3R
To generate a biosensor in which enzyme activity is allos-
terically controlled by a binding domain of a GPCR, we
replaced a 195-amino acid segment of the third ICL
(ICL3) of M3R (amino acid positions 274–469) with the
sequence of luciferase from Photinus pyralis (referred to as
M3R-luci, Figures 1 and 2). Previous studies in mamma-
lian expression systems have shown that in M3R, the
removal of the central part of ICL3 has no significant
effect on receptor function [29-31]. As shown in Figure 3
and summarized in Table 1, M3R-luci expressed in COS-7
cells was delivered to the cell surface and displayed both
luciferase activity (Figure 3A) and carbachol (CCh)-
induced inositol phosphate (IP) formation (Figure 3B).
However, enzyme activity was not influenced by applica-
tion of the agonist CCh but we noted a significant reduc-
tion (15%, p < 0.001) in luciferase activity in the presence
of the inverse agonist atropine (Figure 3A, Table 1). The
effect of atropine was not found when luciferase was
inserted into the second intracellular loop (ICL2) or fused
to a truncated M3R (constructs #21 and #22, Figure 2,
Table 1) and in several other controls (luciferase alone, V2
vasopressin receptor (V2R)) [see Additional file 1] [see
Additional file 2] [see Additional file 3].
Optimization of the M3R-luciferase fusion protein
Next, we systematically deleted portions of ICL3 flanking
the enzyme (Figure 2) to improve coupling of atropine-
induced conformational changes to enzyme activity. Suc-
cessive N-terminal shortening of ICL3 (constructs #1-#5)
progressively reduced cell surface expression, ligand-
induced IP formation and luciferase activity but atropine
failed to modulate luciferase activity. Likewise, the C-ter-
minal part of ICL3 was shortened (constructs #6-#8).
Constructs #6 and #8 were properly delivered to the cell
surface and displayed high luciferase activity. Strikingly,
both chimeras showed a significant reduction in enzyme
activity up to ~40% (construct #8, Table 1) upon atropine
binding. G-protein signalling was retained in construct #6
but abolished in construct #8, presumably because the
deleted C-terminal part of ICL3 is involved in G-protein
coupling [32]. The combination of N- and C-terminal
shortening (construct #9) was not advantageous.
We then tested whether N- or C-terminal truncation of the
luciferase insert improved coupling to conformational
changes of the receptor. Only deletion of the very N-termi-
nal two amino acid residues (construct #10) had a signif-
icant effect on atropine-induced reduction of the enzyme
activity (Table 1). Combination with ICL3 shortening
(construct #11) did not further improve allosteric modu-
lation of the enzyme activity by atropine. In agreement
with previous studies [33], further removal of the N termi-
nus abolished enzyme activity completely (Table 1, con-
structs #12-#18) probably because of destruction of the
functionally relevant N-terminal domain. The crystal
structure of Photinys pyralis luciferase demonstrates that N-
terminal and C-terminal domains form the active site
[34]. C-terminal truncation of the enzyme did not result
in significantly reduced enzyme activity after atropine
application, neither alone (construct #19) nor in combi-
nation with ICL3 truncation (construct #20). Preliminary
studies with fusion proteins of other GPCR and reporterPage 2 of 9
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required for every individual biosensor (data not shown).
Allosteric modulation of luciferase activity by M3R 
blockers
Finally, we investigated the specificity and potency of
other M3R blockers in M3R-luci constructs. Scopolamine
and butylscopolamine, both are inverse agonists at M3R,
were most efficient in reducing luciferase activity in con-
struct #8 [see Additional file 4]. IC50 values for atropine
and scopolamine were 6.6 ± 2.3 nM and 2.1 ± 0.4 nM,
respectively (Figure 4). In agreement with functional stud-
ies at the wild-type M3R [35], butylscopolamine was less
potent in luciferase inhibition (IC50 value: 1.7 ± 0.5 μM,
Figure 4). This indicates an unchanged pharmacology of
the ligand-binding domain within the M3R-luciferase
fusion protein.
From the constructs tested, construct #8 met best the cri-
teria of a biosensor, including nanomolar ligand sensitiv-
ity, high cell surface expression, and reduced G protein-
coupling (Figures 3 and 4, Table 1). In this construct,
structural optimization was successfully used to enhance
coupling of ligand-induced rigid body movement of the
TMH to structural changes within the luciferase domain.
As this leads to a reduction in luciferase activity, one can
speculate that the underlying conformational change rear-
ranges the orientation of the N- and C-terminal domains
within the luciferase molecule that form its active centre.
In addition, our data support previous findings [18,19]
that structural changes upon inverse agonist binding are
different from those induced by agonists. Following CCh
stimulation, fusion protein #6 still activated the Gq/phos-
pholipase C pathway but CCh had no influence on luci-
ferase activity (Table 1). However, atropine reduced
Table 1: Functional properties of wild-type M3R and M3R-luciferase fusion proteins.
luciferase activity IP accumulation (fold over GFP basal) Cell surface 
expression
mutant basal (% of M3R-luci) 100 μM CCh 
(% of basal activity)
100 μM atropine 
(% of basal activity)
basal 100 μM CCh (% of M3R-luci)
M3R 0.08 ± 0.03 (3) - - 2.93 ± 0.37 12.1 ± 2.0 229 ± 13
M3R-luci 100 (31) 105 ± 5 84.6 ± 3.5** 1.60 ± 0.15 10.6 ± 0.2 100
#1 71.2 ± 0.7 (3) 103 ± 9 74.8 ± 9.3 1.40 ± 0.12 9.60 ± 0.45 74.7 ± 5.3
#2 42.8 ± 4.8 (3) 116 ± 5 93.0 ± 4.2 1.20 ± 0.12 4.37 ± 0.09 56.1 ± 4.1
#3 29.8 ± 3.0 (4) 91.0 ± 11.0 95.2 ± 10.9 0.93 ± 0.03 1.57 ± 0.12 32.8 ± 5.3
#4 16.6 ± 3.0 (3) 110 ± 3.8 104 ± 6.8 0.97 ± 0.03 1.10 ± 0.06 13.5 ± 0.7
#5 11.1 ± 1.5 (3) 104 ± 10 96.0 ± 21.2 0.97 ± 0.09 1.10 ± 0.06 3.9 ± 0.9
#6 95.7 ± 5.5 (20) 94.0 ± 7.1 75.7 ± 5.2** 1.27 ± 0.09 9.50 ± 0.61 105 ± 3.2
#7 42.0 ± 3.7 (11) 95.9 ± 7.5 93.8 ± 5.9 1.00 ± 0.10 3.27 ± 0.17 35.8 ± 4.2
#8 62.6 ± 5.2 (22) 98.5 ± 4.7 60.2 ± 2.8** 0.87 ± 0.03 1.37 ± 0.09 114 ± 7
#9 25.9 ± 3.7 (5) 98.4 ± 8.7 87.3 ± 8.6 1.03 ± 0.09 1.43 ± 0.12 27.3 ± 3.5
#10 37.0 ± 4.0 (5) 95.2 ± 7.3 76.4 ± 4.1* 1.53 ± 0.17 9.67 ± 0.78 31.6 ± 4.4
#11 30.3 ± 3.9 (5) 83.4 ± 7.3 73.8 ± 3.1* 1.40 ± 0.06 8.33 ± 0.54 28.9 ± 4.8
#12 37.2 ± 6.8 (4) 111 ± 17 78.6 ± 10.1 1.43 ± 0.17 9.90 ± 0.70 56.6 ± 7.8
#13 27.8 ± 6.7 (3) 80.2 ± 8.3 76.3 ± 8.5 1.13 ± 0.09 8.87 ± 1.01 36.7 ± 11.6
#14 42.0 ± 11.3 (4) 106 ± 10 85.5 ± 6.4 1.50 ± 0.12 9.57 ± 0.95 39.5 ± 4.3
#15 31.8 ± 6.5 (4) 102 ± 5 84.3 ± 7.4 1.10 ± 0.10 8.80 ± 0.95 25.5 ± 2.5
#16 0.4 ± 0.1 (3) - - 1.07 ± 0.09 5.23 ± 0.41 14.6 ± 3.8
#17 0.4 ± 0.1 (3) - - 1.00 ± 0.06 4.40 ± 0.45 12.3 ± 5.7
#18 0.5 ± 0.3 (3) - - 0.87 ± 0.07 1.80 ± 0.15 5.9 ± 2.5
#19 69.3 ± 7.6 (4) 92.3 ± 16.1 66.4 ± 9.4 1.47 ± 0.19 10.9 ± 1.5 76.6 ± 12.6
#20 19.5 ± 1.3 (4) 99.6 ± 4.5 91.8 ± 9.0 0.93 ± 0.09 4.13 ± 0.12 35.2 ± 2.9
#21 17.8 ± 2.4 (7) 99.5 ± 3.3 96.1 ± 4.1 1.07 ± 0.19 1.03 ± 0.07 6.6 ± 1.6
#22 24.3 ± 10.9 (5) 97.4 ± 4.2 97.2 ± 9.1 1.03 ± 0.07 0.93 ± 0.09 0.6 ± 0.5
To evaluate the functional properties of M3R-enzyme chimeras, luciferase activities, measured in the absence (basal activity) and presence of the 
indicated ligands, were determined (see Methods). Basal activity is given as percentage of M3R-luci (411,043 ± 95,142 AU). Activity in the presence 
of ligands is given as percentage of the activity of the individual constructs. Data are presented as means ± S.E.M. of the indicated number of 
experiments, each carried out in triplicate. For measurement of Gq/phospholipase C activation IP accumulation assays were performed as described 
under Methods. Basal IP values were determined in control (GFP)-transfected COS-7 cells (716 ± 81 cpm/well). Data (three independent assays 
performed in triplicate) are given as means ± S.E.M. fold over GFP-transfected IP values. Cell surface expression was assayed with indirect cell 
surface ELISA. Specific optical density (OD) readings (OD value of HA-tagged construct minus OD value of GFP-transfected cells) are given as a 
percentage of M3R-luci. The nonspecific OD (GFP) was 0.156 ± 0.02 (set as 0%) and the OD value of M3R-luci was 0.66 ± 0.06 (set as 100%). ELISA 
data are given as means ± S.E.M. of three independent experiments, each carried out in triplicate.
Significant reduction of the luciferase activity (*p < 0.01; **p < 0.001)Page 3 of 9
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to note that insertion of luciferase, which itself is bigger
than the receptor protein, into the cytoplasmic surface of
the GPCR still allows for efficient G-protein coupling. This
implicates a rather small interaction site between the
receptor and the G protein.
Conclusion
By integration of luciferase into ICL3 of a GPCR and suc-
cessive optimization, we generated a fusion protein in
which the enzyme activity is allosterically modulated by
ligand binding to the GPCR in the nanomolar range.
Thus, we demonstrate that GPCR are suitable as modular
ligand binding domains capable of transducing the signal
through rigid-body movement of TMH onto an intracellu-
larly integrated enzyme. Artificial GPCR-enzyme chimeras
may have applications beyond biosensing, for example, in
ligand-dependent control of metabolic pathways and as
molecular tools to study conformational changes in
GPCR. Our study may also encourage the generation of
GPCR fusion proteins in which other proteins or protein
domains such as fluorescent proteins and SH3 domains
are allosterically regulated to modulate fluorescence prop-
erties and protein-protein interactions, respectively.
Methods
Materials
The agonist carbamylcholine chloride (carbachol, CCh)
and the inverse agonists [36] atropine sulfate, scopo-
lamine hydrochloride, and n-butyl scopolamine bromide
were obtained from Sigma. Substances were solved in
water and stock solutions (100 mM) were aliquoted and
stored at -20°C. Aliquots were thawed only once. All
restriction enzymes for cloning purposes were purchased
from NEB and primers [see Additional file 5] were synthe-
sized by Invitrogen.
Construction of plasmids and mutants of mAChR
All mutations were introduced into the rat M3R [30]. In
this rat M3R construct the central part of ICL3 was
removed and the N- and C terminus contained an HA-
and a Flag-tag, respectively. These modifications were pre-
viously demonstrated to have no significant effect on
receptor function [29-31].
The cDNA from Photinus pyralis luciferase (without start
and stop codons) was amplified and introduced into the
ICL3 of M3R by a PCR-based strategy. Luciferase cDNA
was 5' and 3' flanked by SpeI sites which allowed for sys-
tematic and convenient shortening of ICL3 during optimi-
zation experiments. All other mutations were introduced
by PCR-based and fragment replacement strategies into
M3R-luci (Figure 1 and 2). For control purposes, several
additional constructs were generated. Here, luciferase was
integrated into ICL2 (Figure 2, construct #21) or C-termi-
nally fused to M3R that was truncated in ICL3 (Figure 2,
construct #22). Moreover, luciferase was also integrated
into V2R lacking the central portion of ICL3 (positions
R243 – T253). The identity of all constructs and the correct-
ness of all PCR-derived sequences were confirmed by
restriction analysis and DNA sequencing.
COS-7 cell culture and transfection
COS-7 cells were grown in Dulbecco's modified Eagle
medium (DMEM, Invitrogen) supplemented with 10%
fetal bovine serum (FBS), 100 U/ml penicillin, and 100
μg/ml streptomycin at 37°C in a humidified 7% CO2
incubator. Rotifect (Roth) was used for transient transfec-
tion. For measurement of luciferase activity, 6 × 105 cells
were seeded into 6-cm dishes and transfected with 2 μg of
plasmid DNA. Twenty-four hours after transfection, cells
were split into white 96-well culture plates (PerkinElmer)
at 30,000 cells per well. IP formation was determined in
12-well plates (1.5 × 105 cells/well transfected with 0.5 μg
of plasmid DNA/well). For the measurement of cell sur-
face expression, cells were seeded into 48-well plates (3.5
Schematic presentation of the M3R-luciferase fusion con-structFigure 1
Schematic presentation of the M3R-luciferase fusion 
construct. Outline of M3R-luci with detailed illustration of 
ICL3 containing the luciferase sequence. Details of all fusion 
constructs are given in Figure 2.Page 4 of 9
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Fusion constructs and deletion mutants used in the studyigure 2
Fusion constructs and deletion mutants used in the study. Mutants were generated by successive deletion of N- and C-
terminal domains of the enzyme and loop portions of the receptor (deleted portions are given). For control experiments luci-
ferase was also integrated into ICL2 (#21) and fused to a truncated M3R only consisting of TMH1-5 (#22).
BMC Biotechnology 2009, 9:46 http://www.biomedcentral.com/1472-6750/9/46× 104 cells/well) and transfected with 0.2 μg of plasmid
DNA/well.
Functional assays
To measure IP formation transfected COS-7 cells were
incubated with 2 μCi/ml of myo-3H-inositol (18.6 Ci/
mmol, PerkinElmer) for 18 h. Thereafter, cells were
washed once with serum-free DMEM containing 10 mM
LiCl, followed by incubation with ligands for 30 min at
37°C. Intracellular IP levels were determined by anion-
exchange chromatography as described previously [37].
The luciferase activity assay was performed with a luci-
ferase activity detection system based on the method
described by van Leeuwen et al. [38]. Briefly, after incuba-
tion with the ligand in DMEM for 20 min at 37°C, cells
were washed with ice-cold PBS. Cell lysis was performed
on ice by adding 20 μl of lysis buffer (77 mM K2HPO4, 23
mM KH2PO4, 0.2% Triton X-100, 1 mM DTT, pH 7.8) per
well. The lysate was mixed with 100 μl of luciferase buffer
(20 mM tricine, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3
mM DTT, 270 μM coenzyme A, 530 μM ATP, 470 μM d-
luciferin, pH 7.8). After 3 min luminescence was meas-
ured for 1 sec with a Victor2-1420 Multilabel counter
(PerkinElmer). Prior to data-collecting functional assays,
several tests were performed to ascertain the adequate
time for cell lysis and incubation with luciferase buffer.
Since both buffers did not contain ligands, diffusion from
the receptor was possible. The ligand-induced changes in
luciferase activity were stable for at least 10 min after cell
lysis [see Additional file 6].
To estimate receptor surface expression, we used an indi-
rect cellular ELISA [39]. Three days after transfection cells
were fixed with 4% formaldehyde in PBS for 30 min at
room temperature. After washing with PBS and blocking
with 10% FBS in DMEM at 37°C for 1 h cells were incu-
bated with biotinylated anti-HA-antibody (Roche, 1 μg/
ml in DMEM with 10% FBS) at room temperature for 2 h.
Plates were washed and incubated with streptavidin-
horse-radish peroxidase conjugate (Roche, 1:5000 dilu-
tion in DMEM with 10% FBS) at room temperature for 1
h, followed by extensive washing. Enzymatic reactions
were carried out at room temperature in the presence of
H2O2 and o-phenylenediamine. The reaction was stopped
by adding 50 μl of 50 mM Na2SO3 in 1 M HCl. Colour
development was measured bichromatically at 492 nm
and 620 nm using a Sunrise™ plate reader (Tecan).
Functional integration of luciferase into the M3 muscarinic acetylcholine receptorigure 3
Functional integration of luciferase into the M3 muscarinic acetylcholine receptor. A) COS-7 cells were transfected 
with luciferase construct, M3R-luci and construct #8 and luciferase activity was determined after incubation without and with 
the indicated ligands. The luminescences without ligands were 1,905,212 ± 172,463 AU (luciferase), 196,512 ± 4,942 AU (M3R-
luci) and 100,473 ± 9,770 AU (#8). All data are given as means ± SEM of three independent experiments each performed in 
triplicate. B) Basal and CCh-induced IP formation was determined in COS-7 cells transfected with the wild-type M3R, M3R-luci 
and construct #8. All data are given as means ± SEM of three independent experiments each performed in triplicate.Page 6 of 9
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Allosteric modulation of enzyme activity in M3R-luciferase fusion proteins by nanomolar concentrations of M3R blockersFigur  4
Allosteric modulation of enzyme activity in M3R-luciferase fusion proteins by nanomolar concentrations of 
M3R blockers. CCh (square), atropine (open circle), scopolamine (filled circle) and butylscopolamine (diamond) were applied 
at the indicated concentrations on COS-7 cells transfected with M3R-luci (A) and construct #8 (B) and luciferase activity was 
determined. The luminescences without ligands were 178,680 ± 18,171 AU (M3R-luci) and 121,578 ± 12,845 AU (construct 
#8). Enzyme activity of the individual constructs without ligands was set at 100%. All data are given as mean ± S.E.M. of four 
independent experiments each performed in triplicate. Control experiments were carried out with COS-7 cells expressing 
luciferase alone and V2R-luci [see Additional file 3].A paired, two-tailed Student's t-test was used to detect sig-
nificant differences in luciferase activity after ligand bind-
ing. The number of replicates is given in the respective
legends of the figures and table.
Abbreviations
AU: arbitrary units; FBS: fetal bovine serum; CCh: carba-
chol; DMEM: Dulbecco's modified Eagle medium; ICL1-
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muscarinic acetylcholine receptor; TMH: transmembrane
helix; V2R: V2 vasopressin receptor.
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Description of control experiments. This file summarises all control 
experiments carried out.




Luciferase can be integrated into other GPCR (e.g. V2R) without loos-
ing G protein-coupling abilities. COS-7 cells were transfected with wild 
type V2R and V2R-luci. 48 h after transfection cells were incubated with 
100 nM arginine-vasopressin (AVP). Cyclic AMP levels were determined 
using the non-radioactive cAMP-determination kit (AlphaScreening tech-
nology, PerkinElmer). The cAMP level (atmol/cell) of two independent 
experiments performed in triplicate is given (means ± S.E.M.).




M3R ligands have no effect on soluble luciferase and V2R-luciferase 
fusion protein. COS-7 cells were transfected with luciferase (A) and 
V2R-luci (B). Increasing concentrations of CCh (square), atropine (open 
circle), scopolamine (filled circle) and butylscopolamine (diamond) were 
applied and luciferase activity was determined as described under Meth-
ods. The enzyme activities without ligands were 1,905,212 ± 172,463 
AU (luciferase), 182,120 ± 18,188 AU (V2R-luci). Enzyme activity of 
the individual constructs without ligands was set 100%. All data are given 
as mean ± S.E.M. of three independent experiments each performed in 
triplicate.
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Modulation of enzyme activity in M3R-luciferase fusion proteins by 
different receptor ligands. COS-7 cells transfected with M3R-luci and 
construct #8 were stimulated with the indicated ligands (100 μM) and 
luciferase activity was determined. The luminescence of the fusion con-
structs were 184,314 ± 75,049 AU (M3R-luci) and 140,452 ± 55,426 
AU (construct #8). Enzyme activity of the individual constructs without 
ligands were set 100%. All data are given as mean ± S.E.M. of four inde-
pendent experiments each performed in triplicate.




Primer used in this study. This table listes all primers used to generate 
the mutants of the M3R-luciferase fusion protein.




Kinetics of luciferase activity assay. Cells were transfected with M3R-
luci and luciferase and the assay was performed as described in the 
Method section with the exception that the luciferase buffer was added at 
different incubation times after lysis. Data are given as mean ± S.D. of 
one experiment performed in triplicate.
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